SILO · Silo Pharma, Inc.
$4.30
-0.16 (-3.59%)
At close · Jul 29
Going-concern doubt
— cleared May 14, 2026
The latest filing states the doubt was alleviated.
“The positive working capital serves to mitigate the conditions that historically raised substantial doubt about the Company's ability to continue as a going concern. The Company believes that it has sufficient cash and liquid short-term investments to meet its obligations for a minimum of twelve months from the date of this filing.”View the 10-Q filed May 14, 2026
Market Cap
$69.95M
Shares
16.27M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Eric Weisblum | CEO | $521,750 |
| Daniel Ryweck | CFO | $101,494 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Eric Weisblum | CEO | $630,051 |
| Daniel Ryweck | CFO | $88,600 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Eric Weisblum | CEO | $569,009 |
| Daniel Ryweck | CFO | $62,692 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Eric Weisblum | CEO | $332,250 |
| Daniel Ryweck | CFO | $15,000 |